CMRX - CHIMERIX INC
IEX Last Trade
3.33
2.466 74.063%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$0.86
2.47
285.55%
Fundamental analysis
12%
Profitability
0%
Dept financing
3%
Liquidity
75%
Performance
10%
Performance
5 Days
11.71%
1 Month
274.48%
3 Months
295.31%
6 Months
259.14%
1 Year
258.68%
2 Year
94.19%
Key data
Stock price
$3.33
DAY RANGE
$0.86 - $3.08
52 WEEK RANGE
$0.81 - $3.39
52 WEEK CHANGE
$252.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Michael A. Sherman
Region: US
Website: chimerix.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: chimerix.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Chimerix, Inc. develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
Recent news